Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive symbols : LIFE save search
aTyr Pharma Presents New Data on Efzofitimod Mechanism of Action and Positive Exposure-Response at the American Thoracic Society 2023 International Conference
Published: 2023-05-22 (Crawled : 12:00) - globenewswire.com
LIFE | $1.62 -1.22% -1.23% 220K
|
Health Technology
|
| O: 2.05%
H: 0.8%
C: -2.01%
pharma conference positive international efzofitimod
aTyr Pharma Announces Publication of Positive Data from Phase 1b/2a Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal CHEST
Published: 2022-11-09 (Crawled : 15:00) - biospace.com/
LIFE | $1.62 -1.22% -1.23% 220K
|
Health Technology
|
| O: 0.0%
H: 0.21%
C: -4.62%
treatment pharma positive publication study phase 2b
aTyr Pharma Announces Positive End-of-Phase 2 Meeting with FDA on Efzofitimod for the Treatment of Pulmonary Sarcoidosis
Published: 2022-03-10 (Crawled : 14:00) - globenewswire.com
LIFE | $1.62 -1.22% -1.23% 220K
|
Health Technology
|
| O: 3.62%
H: 6.6%
C: 2.33%
treatment fda phase 2 pos positive
aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Announce Positive Data from a Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response of ATYR1923 in Pulmonary Sarcoidosis
Published: 2021-09-13 (Crawled : 12:00) - globenewswire.com
LIFE | $1.62 -1.22% -1.23% 220K
|
Health Technology
|
| O: 14.96%
H: 47.46%
C: 45.24%
biopharma phase 1 positive trial phase 1b phase 2b
aTyr Pharma Announces Positive Data from Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response for ATYR1923 in Pulmonary Sarcoidosis
Published: 2021-09-13 (Crawled : 12:00) - globenewswire.com
LIFE | $1.62 -1.22% -1.23% 220K
|
Health Technology
|
| O: 14.96%
H: 47.46%
C: 45.24%
phase 1 positive trial phase 1b phase 2b response
aTyr Pharma Announces Positive Biomarker Data from Phase 2 Clinical Trial of ATYR1923 Demonstrating Anti-Inflammatory Effects in COVID-19 Patients with Severe Respiratory Complications
Published: 2021-03-15 (Crawled : 15:00) - biospace.com/
LIFE | $1.62 -1.22% -1.23% 220K
|
Health Technology
|
| O: 4.41%
H: 1.42%
C: -5.39%
covid phase 2 positive respiratory trial biomarkers
aTyr Pharma Announces Positive Topline Results from Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications
Published: 2021-01-04 (Crawled : 22:00) - globenewswire.com
LIFE | $1.62 -1.22% -1.23% 220K
|
Health Technology
|
| O: 0.5%
H: 4.01%
C: -3.51%
covid positive results respiratory trial topline phase 2
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.